Thus, gaining control over IRE1α’s activities with small molecules remains a promising approach to improving cancer treatments by inhibiting IRE1α activity during the early stages of tumorigenesis [53–55] and by preventing tumor progression and metastasis either by utilizing proapoptotic abilities of this enzyme [4] or inducing apoptosis through other signaling pathways such as PERK. The gene discussed is EIF2AK3; the disease is cancer.